Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 8.01 (Other Events). Phase 3 EXPAND met its primary endpoint and all five prespecified secondary endpoints, strengthening LIVMARLI’s expansion case.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 EXPAND met its primary endpoint and all five prespecified secondary endpoints, strengthening LIVMARLI’s expansion case
- Pediatric pruritus improved 0.98 points versus placebo, p=0.0004, with serum bile acids falling 69.0% versus placebo, p<0.0001
- Biliary atresia patients with native livers showed a 1.15-point pruritus treatment effect and 73.1% serum bile acid treatment effect
- Safety was broadly comparable, but diarrhea occurred in 64.0% of LIVMARLI patients versus 11.1% on placebo
- Supplemental U.S. New Drug Application planned for the first half of 2027, creating a regulatory catalyst and potential market expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.